Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Synthetic Biology: Amplifying Throughput in Discovery at Marginal Cost

This article was originally published in Start Up

Executive Summary

An example of the looming power of synthetic biology, one of its first start-ups, Codon Devices, is providing researchers with hundreds of specified protein variants using automated, microarray-based fabrication methods. Its platform could help address pharma's productivity problem by decreasing the size of a discovery pipeline and shrinking the development timeline, and position the company to negotiate downstream payments for its efforts based on the success of clients' development programs.

You may also be interested in...



The Climate for Investing in Platform Technologies

The founder and CEO of Flagship Ventures, Noubar Afeyan, points to several reasons why early-stage investing should be on the upswing.

The Climate for Investing in Platform Technologies

The founder and CEO of Flagship Ventures, Noubar Afeyan, points to several reasons why early-stage investing should be on the upswing.

A Creative Approach to Third World Markets and to one Start-Up's First Financing

A new three-way agreement between the University of California, Berkeley (UCB), the Gates Foundation, Amyris Biotechnologies Inc., and the Institute for OneWorld Health (IOWH) showcases one approach to creating affordable drugs for third-world markets that aren't attractive to for-profit companies-with incentives for all participants.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132553

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel